KarunaNews Story

For the first time, a malaria treatment designed specifically for infants and babies under 4.5 kilograms has hit the scene. Thanks to Novartis and a Swiss non-profit, Coartem Baby has been approved and is set to launch in Africa in just weeks. "We saw a gap here," Novartis' president of global health stated, addressing the urgent need for this age group. While traditional treatments have been risky for such young ones, this new oral medicine dissolves in water and promises to be a game-changer, particularly when combined with vaccines and bed nets. Eight African countries, including Uganda and Tanzania, are on the verge of approving this life-saving medication. A guest column by Krystal Birungi in Semafor highlights a radical genetic approach targeting malaria-carrying mosquitoes, suggesting "a new frontier in the fight against malaria." As Africa battles around 263 million cases annually, these innovative treatments offer a beacon of hope for the continent's most vulnerable.